Campbell & CO Investment Adviser LLC Increases Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Campbell & CO Investment Adviser LLC raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 34.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,476 shares of the medical equipment provider’s stock after buying an additional 2,433 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Zimmer Biomet were worth $1,153,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Primecap Management Co. CA boosted its position in shares of Zimmer Biomet by 10.5% during the fourth quarter. Primecap Management Co. CA now owns 5,086,578 shares of the medical equipment provider’s stock valued at $619,037,000 after buying an additional 484,151 shares during the period. American Century Companies Inc. boosted its position in shares of Zimmer Biomet by 21.2% during the third quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after buying an additional 852,186 shares during the period. Victory Capital Management Inc. boosted its position in shares of Zimmer Biomet by 3.9% during the fourth quarter. Victory Capital Management Inc. now owns 3,199,302 shares of the medical equipment provider’s stock valued at $389,355,000 after buying an additional 118,839 shares during the period. Van ECK Associates Corp raised its stake in shares of Zimmer Biomet by 23.7% during the fourth quarter. Van ECK Associates Corp now owns 2,838,558 shares of the medical equipment provider’s stock valued at $345,452,000 after acquiring an additional 543,344 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Zimmer Biomet by 16.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,760,021 shares of the medical equipment provider’s stock valued at $335,895,000 after acquiring an additional 386,019 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on ZBH. Barclays decreased their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 9th. Citigroup lifted their price target on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, May 30th. Finally, Canaccord Genuity Group reissued a “hold” rating and issued a $130.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $133.75.

Check Out Our Latest Analysis on ZBH

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $113.44 on Wednesday. The business’s fifty day simple moving average is $121.75 and its 200-day simple moving average is $122.06. The company has a market cap of $23.34 billion, a PE ratio of 24.55, a PEG ratio of 2.04 and a beta of 1.02. The company has a current ratio of 1.66, a quick ratio of 0.80 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $147.50.

Zimmer Biomet (NYSE:ZBHGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.07. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.89 earnings per share. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

About Zimmer Biomet

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Stories

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.